Pfizer has entered into an agreement with Arvinas to jointly develop and commercialize ARV-471. It is an oral drug for the treatment of patients with locally advanced or metastatic breast cancer, which is in Phase 2 trials. As part of the agreement, Pfizer will pay Arvinas $650 million and acquire $350 million of the company's common stock.
Pfizer has entered into an agreement with Arvinas to jointly develop and commercialize ARV-471. It is an oral drug for the treatment of patients with locally advanced or metastatic breast cancer, which is in Phase 2 trials. As part of the agreement, Pfizer will pay Arvinas $650 million and acquire $350 million of the company's common stock. 
investors.pfizer.com
English (US) 